<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392637</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0524</org_study_id>
    <secondary_id>NCI-2015-00578</secondary_id>
    <secondary_id>2014-0524</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02392637</nct_id>
  </id_info>
  <brief_title>Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers</brief_title>
  <official_title>A Phase II Study of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well gemcitabine hydrochloride, cisplatin, and nab-paclitaxel&#xD;
      (paclitaxel albumin-stabilized nanoparticle formulation) work in treating patients with&#xD;
      biliary cancers (which includes the gallbladder and bile ducts inside and outside the liver)&#xD;
      that have spread to other places in the body and usually cannot be cured or controlled with&#xD;
      treatment. Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, and&#xD;
      paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells, by stopping them from dividing, or by&#xD;
      stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill&#xD;
      more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the progression-free survival (PFS) of gemcitabine hydrochloride (gemcitabine),&#xD;
      cisplatin, and nab-paclitaxel in advanced, untreated biliary cancers (intrahepatic&#xD;
      cholangiocarcinomas, extrahepatic cholangiocarcinomas, and gallbladder cancers).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the response rate (RR) and disease control rate (partial response + complete&#xD;
      response + stable disease) of gemcitabine, cisplatin, and nab-paclitaxel in advanced biliary&#xD;
      cancers.&#xD;
&#xD;
      II. Determine overall survival (OS) of gemcitabine, cisplatin, and nab-paclitaxel in advanced&#xD;
      biliary cancers.&#xD;
&#xD;
      III. Evaluate the toxicity of gemcitabine, cisplatin, and nab-paclitaxel in advanced biliary&#xD;
      cancers.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Correlate the carbohydrate antigen (CA) 19-9 response (defined as &gt;50% decrease from&#xD;
      baseline) with tumor response, PFS and OS.&#xD;
&#xD;
      II. Assess ribonucleotide reductase subunit MI (RRMI), excision repair cross-complementation&#xD;
      group 1 (ERCC1) pre-treatment status and correlate with tumor response, PFS and OS on an&#xD;
      exploratory basis.&#xD;
&#xD;
      III. Collect optional blood and tissue at the start of treatment and at progression to&#xD;
      explore mechanisms of resistance.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously (IV)&#xD;
      over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30&#xD;
      minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days and then every 3&#xD;
      months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2015</start_date>
  <completion_date type="Actual">August 13, 2020</completion_date>
  <primary_completion_date type="Actual">August 13, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The Bayes factor single arm time-to-event model by Johnson &amp; Cook will be used to monitor the PFS time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 35 days post-treatment</time_frame>
    <description>Toxicity will be monitored closely using the method of Thall et al.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Stage III Intrahepatic Cholangiocarcinoma AJCC v7</condition>
  <condition>Stage IIIA Gallbladder Cancer AJCC v7</condition>
  <condition>Stage IIIB Gallbladder Cancer AJCC v7</condition>
  <condition>Stage IVA Gallbladder Cancer AJCC v7</condition>
  <condition>Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7</condition>
  <condition>Stage IVB Gallbladder Cancer AJCC v7</condition>
  <condition>Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7</condition>
  <condition>Unresectable Extrahepatic Bile Duct Carcinoma</condition>
  <condition>Unresectable Gallbladder Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (nab-paclitaxel, cisplatin, gemcitabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nab-paclitaxel, cisplatin, gemcitabine)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone's Chloride</other_name>
    <other_name>Peyrone's Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nab-paclitaxel, cisplatin, gemcitabine)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
    <other_name>LY188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (nab-paclitaxel, cisplatin, gemcitabine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (nab-paclitaxel, cisplatin, gemcitabine)</arm_group_label>
    <other_name>ABI 007</other_name>
    <other_name>ABI-007</other_name>
    <other_name>Abraxane</other_name>
    <other_name>Albumin-bound Paclitaxel</other_name>
    <other_name>Albumin-Stabilized Nanoparticle Paclitaxel</other_name>
    <other_name>Nanoparticle Albumin-bound Paclitaxel</other_name>
    <other_name>Nanoparticle Paclitaxel</other_name>
    <other_name>paclitaxel albumin-stabilized nanoparticle formulation</other_name>
    <other_name>Protein-bound Paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must have histologically or cytologically confirmed intrahepatic&#xD;
             cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer or may&#xD;
             undergo a repeat biopsy for histologic confirmation if pre-existing biopsy is not&#xD;
             sufficient for diagnosis&#xD;
&#xD;
          -  Metastatic or unresectable disease documented on diagnostic imaging studies&#xD;
&#xD;
          -  May not have received prior chemotherapy; if patient has received prior adjuvant&#xD;
             therapy, must be &gt; 6 months from treatment&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1,500 cells/mm^3&#xD;
&#xD;
          -  Platelets &gt;= 100,000/ul&#xD;
&#xD;
          -  Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 mg/dL (in patients with known Gilbert's syndrome direct&#xD;
             bilirubin =&lt; 1.5 x upper limit of normal [ULN] will be used as organ function&#xD;
             criteria, instead of total bilirubin)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = &lt; 5 x ULN&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 gm/dL&#xD;
&#xD;
          -  Negative serum or urine pregnancy test in women with childbearing potential (WOCBP)&#xD;
             defined as not post-menopausal for 12 months or no previous surgical sterilization,&#xD;
             within one week prior to initiation of treatment; WOCBP must be using an adequate&#xD;
             method of contraception to avoid pregnancy throughout the study and for up to 12 weeks&#xD;
             after the last dose of study drug to minimize the risk of pregnancy&#xD;
&#xD;
          -  A male subject of fathering potential must use an adequate method of contraception to&#xD;
             avoid conception throughout the study and for up to 12 weeks after the last dose of&#xD;
             study drug to minimize the risk of pregnancy; if the partner is pregnant or&#xD;
             breastfeeding, the subject must use a condom&#xD;
&#xD;
          -  Patients must sign an informed consent and authorization indicating that they are&#xD;
             aware of the investigational nature of this study and the known risks involved&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Peripheral neuropathy of grade 2 or greater by Common Terminology Criteria for Adverse&#xD;
             Events (CTCAE) 4.0; in CTCAE version 4.0 grade 2 sensory neuropathy is defined as&#xD;
             &quot;moderate symptoms; limiting instrumental activities of daily living (ADLs)&quot;&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled medical conditions which could compromise&#xD;
             participation in the study such as unstable angina, myocardial infarction within 6&#xD;
             months, unstable symptomatic arrhythmia, uncontrolled diabetes, serious active or&#xD;
             uncontrolled infection&#xD;
&#xD;
          -  Pregnancy (positive pregnancy test) or lactation&#xD;
&#xD;
          -  Known central nervous system (CNS) disease, except for treated brain metastasis;&#xD;
             treated brain metastases are defined as having no evidence of progression or&#xD;
             hemorrhage after treatment and no ongoing requirement for dexamethasone, as&#xD;
             ascertained by clinical examination and brain imaging (magnetic resonance imaging&#xD;
             [MRI] or computed tomography [CT]) during the screening period; anticonvulsants&#xD;
             (stable dose) are allowed; treatment for brain metastases may include whole brain&#xD;
             radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, linear accelerator [LINAC], or&#xD;
             equivalent) or a combination as deemed appropriate by the treating physician; patients&#xD;
             with CNS metastases treated by neurosurgical resection or brain biopsy performed&#xD;
             within 3 months prior to day 1 will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milind Javle</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 1, 2021</submitted>
    <returned>September 28, 2021</returned>
    <submitted>November 1, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

